Status:

UNKNOWN

Micronized Purified Flavonoid- Fraction (MPFF) in the Management of Radiation Proctitis

Lead Sponsor:

Medical University Innsbruck

Collaborating Sponsors:

Servier Affaires Médicales

Conditions:

Proctitis Radiation

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

national and multi-center trial for medical therapy of chronic radiation proctitis inducing anorectal bleedings

Detailed Description

Radiation proctitis is an inflammation of rectal mucosa, a complication following radiation therapy for cancers of the prostate, cervix, uterus, bladder and other malignancies in the pelvic area. Arou...

Eligibility Criteria

Inclusion

  • signed informed consent form
  • male and female patients
  • age ≥ 18 years
  • patients with diagnosis of radiation proctitis with macroscopic bleeding
  • end of radiotherapy ≥ 3 month = 90 days ago

Exclusion

  • infectious proctitis
  • ulcerative proctitis (inflammatory bowel disease)
  • persons unable to understand the informed consent
  • persons, who are in dependent relationship with the study investigators or Sponsor
  • pregnant or lactating women
  • participation in an interventional study

Key Trial Info

Start Date :

February 26 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 26 2023

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT04335617

Start Date

February 26 2020

End Date

August 26 2023

Last Update

November 3 2020

Active Locations (11)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (11 locations)

1

Medizinische Universität Innsbruck

Innsbruck, Tyrol, Austria, 6020

2

Krankenhaus der Stadt Dornbirn

Dornbirn, Austria, 6850

3

Barmherzige Brüder Krankenhaus Graz

Graz, Austria, 8020

4

Medizinische Universität Graz

Graz, Austria, 8036

Micronized Purified Flavonoid- Fraction (MPFF) in the Management of Radiation Proctitis | DecenTrialz